Study of AZD4063 for PLN R14del dilated cardiomyopathy
Part of Genetic & congenital, Heart & circulation clinical trials.
This trial tests a new drug called AZD4063 for people with dilated cardiomyopathy caused by a specific genetic change (PLN R14del mutation). The goal is to see if the drug can improve heart function, and it requires participants to have an ICD or CRT-D device.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old and have a specific genetic mutation called R14 del in the PLN gene.
- Your heart’s pumping ability (ejection fraction) must be 45% or less, as measured by an echocardiogram.
- You must have a heart device like an ICD or CRT-D already implanted.
- You need to be on stable heart failure medications for at least 6 weeks before the trial starts.
- You cannot have other serious heart conditions, recent heart rhythm problems requiring treatment, or significant liver or kidney lab abnormalities.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining modern heart failure medications with an implantable defibrillator (ICD) can reduce the risk of dangerous heart rhythms and improve survival in people with dilated cardiomyopathy. It focuses on those with a weak heart pump and specific scarring seen on MRI.
This trial tests a new study drug called AZD1613 for adults with a certain type of kidney disease (ADPKD). Researchers want to see if it is safe, how the body handles it, and what the right dose might be.
This trial is testing a personalized approach to deciding who gets an implantable defibrillator (ICD) for people with heart failure due to dilated cardiomyopathy (not from blocked arteries). It aims to see if MRI scans and other factors can better match the device to those who need it most.
This trial tests if danicamtiv can improve heart function in people with dilated cardiomyopathy caused by certain genetic changes. It may help those who have stable symptoms but still need more treatment options.
This trial tests a new drug called AZD6793 for people with moderate to very severe COPD. It aims to see if the drug can help improve breathing and reduce flare-ups.
This trial tests an experimental drug called NVC-001 for people with a specific genetic heart condition (LMNA-related dilated cardiomyopathy) that causes the heart to become weak and enlarged. The goal is to see if the drug can help improve heart function.
Hear when a new Dilated Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.